Comparison of Semaglutide and Lifestyle Counselling for Weight Loss Using Multi-Site Electronic Health Records

IF 2.1 Q3 ENDOCRINOLOGY & METABOLISM

Clinical Obesity Pub Date : 2026-03-13 DOI:10.1111/cob.70076

William J. B. Powell, Diego R. Mazzotti, Stephen D. Herrmann, Ann M. Davis, Bettina Mittendorfer, Jared Bruce, Xing Song, Lemuel R. Waitman

{"title":"Comparison of Semaglutide and Lifestyle Counselling for Weight Loss Using Multi-Site Electronic Health Records","authors":"William J. B. Powell, Diego R. Mazzotti, Stephen D. Herrmann, Ann M. Davis, Bettina Mittendorfer, Jared Bruce, Xing Song, Lemuel R. Waitman","doi":"10.1111/cob.70076","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>To evaluate the effectiveness of semaglutide compared with lifestyle counselling alone for weight loss in diabetic and non-diabetic patients with obesity. This multi-site, retrospective, observational study uses data from electronic health records which are part of the Greater Plains Collaborative (GPC) in a time-to-event analysis for comparative effectiveness. Participants were adults with obesity receiving semaglutide for a minimum of 16 weeks or lifestyle counselling with at least three sessions within the first 16 weeks. The primary outcome is incidence of 10% or greater reduction in weight from baseline. Of 3927 eligible participants, 615 were prescribed semaglutide and 3312 received lifestyle counselling. Following propensity score matching, each group (diabetic and non-diabetic) consisted of 120 and 495 participants, respectively. Hazard ratios for 10% weight loss were significantly higher from semaglutide for non-diabetic (1.63 [95% CI: 1.32, 2.01; <i>p</i> < 0.001]) and diabetic (2.45 [95% CI: 1.47, 4.09; <i>p</i> < 0.001]) populations. These data from our study suggest that semaglutide therapy compared with lifestyle counselling alone is more effective in achieving at least 10% weight loss. This information may be used to inform clinical practice guidelines and stimulate future research on the long-term effectiveness of various weight loss options for individuals with obesity.</p>\n </div>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 2","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Obesity","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cob.70076","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

To evaluate the effectiveness of semaglutide compared with lifestyle counselling alone for weight loss in diabetic and non-diabetic patients with obesity. This multi-site, retrospective, observational study uses data from electronic health records which are part of the Greater Plains Collaborative (GPC) in a time-to-event analysis for comparative effectiveness. Participants were adults with obesity receiving semaglutide for a minimum of 16 weeks or lifestyle counselling with at least three sessions within the first 16 weeks. The primary outcome is incidence of 10% or greater reduction in weight from baseline. Of 3927 eligible participants, 615 were prescribed semaglutide and 3312 received lifestyle counselling. Following propensity score matching, each group (diabetic and non-diabetic) consisted of 120 and 495 participants, respectively. Hazard ratios for 10% weight loss were significantly higher from semaglutide for non-diabetic (1.63 [95% CI: 1.32, 2.01; p < 0.001]) and diabetic (2.45 [95% CI: 1.47, 4.09; p < 0.001]) populations. These data from our study suggest that semaglutide therapy compared with lifestyle counselling alone is more effective in achieving at least 10% weight loss. This information may be used to inform clinical practice guidelines and stimulate future research on the long-term effectiveness of various weight loss options for individuals with obesity.

查看原文本刊更多论文

使用多站点电子健康记录进行西马鲁肽和生活方式减肥咨询的比较

评价西马鲁肽与单纯生活方式咨询对糖尿病和非糖尿病合并肥胖患者减肥的效果。这项多地点、回顾性、观察性研究使用来自电子健康记录的数据，这些数据是大平原协作组织（GPC）的一部分，用于对相对有效性进行时间到事件分析。参与者是肥胖的成年人，接受至少16周的西马鲁肽治疗，或在前16周内至少进行三次生活方式咨询。主要结局是体重较基线减少10%或更多。在3927名符合条件的参与者中，615人服用了西马鲁肽，3312人接受了生活方式咨询。根据倾向评分匹配，每组（糖尿病和非糖尿病）分别由120和495名参与者组成。非糖尿病患者服用西马鲁肽后体重减轻10%的风险比显著升高(1.63 [95% CI: 1.32, 2.01; p

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Obesity ENDOCRINOLOGY & METABOLISM-

CiteScore

5.90

自引率

3.00%

发文量

期刊介绍： Clinical Obesity is an international peer-reviewed journal publishing high quality translational and clinical research papers and reviews focussing on obesity and its co-morbidities. Key areas of interest are: • Patient assessment, classification, diagnosis and prognosis • Drug treatments, clinical trials and supporting research • Bariatric surgery and follow-up issues • Surgical approaches to remove body fat • Pharmacological, dietary and behavioural approaches for weight loss • Clinical physiology • Clinically relevant epidemiology • Psychological aspects of obesity • Co-morbidities • Nursing and care of patients with obesity.